Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.53 |
| ▸ | DRD4 | P21917 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 7/20 | 0.51 |
| ▸ | HTR7 | P34969 | 5/20 | 0.51 |
| ▸ | HTR6 | P50406 | 4/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL210345 | 0.87 | HTR2A (0.53) | DRD2DRD4SIGMAR1HTR2AHTR7 | |
| SCHEMBL14629552 | 0.84 | HTR2A (0.48) | DRD2DRD4SIGMAR1HTR2AHTR7 | |
| SCHEMBL2734696 | 0.83 | DRD2 (0.49) | DRD2DRD4SIGMAR1HTR2AHTR7 | |
| SCHEMBL2734694 | 0.82 | HTR2A (0.51) | DRD2DRD4SIGMAR1HTR2AHTR7 | |
| SCHEMBL13453339 | 0.79 | HTR2A (0.49) | DRD2DRD4SIGMAR1HTR2AHTR7 | |
| SCHEMBL2734082 | 0.79 | HTR2A (0.57) | DRD2DRD4SIGMAR1HTR2AHTR7 | |
| SCHEMBL2733574 | 0.75 | HTR2C (0.53) | DRD2DRD4HTR2A | |
| SCHEMBL2976277 | 0.74 | GBA1 (0.52) | DRD2DRD4SIGMAR1HTR2AHTR7 | |
| SCHEMBL2734240 | 0.74 | HTR2C (0.53) | DRD2HTR2A | |
| SCHEMBL2733202 | 0.74 | HTR2C (0.51) | DRD2HTR2AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088778-B2 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088778-B2 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090163514-A1 | BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF | COUGHLIN DANIEL | 2009-06-25 | — | — | US | disclosed |
| US-20090163514-A1 | BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF | COUGHLIN DANIEL | 2009-06-25 | — | — | US | disclosed |
| US-7494998-B2 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7494998-B2 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | GABRA5, HCRTR2, HCRTR1 | DRD2 1869/4885DRD4 1256/4885SIGMAR1 693/4885 |
| US-20090163514-A1 | BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF | GABRA5, HCRTR2, HCRTR1 | DRD2 1869/4885DRD4 1256/4885SIGMAR1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.